Vignot Stéphane, Besse Benjamin
Service d'oncologie médicale, Groupe hospitalier Diaconesses-Croix Saint Simon, 18 rue du Sergent Bauchat, 75012 Paris.
Bull Cancer. 2007;94 Spec No Actualites:S95-103.
Questions raised during gemcitabine development reflect non small-cell lung cancer (NSCLC) history during last 10 years. Third generation therapies (gemcitabine, vinorelbine and taxanes) combined with platinium compounds are now to be prescribed in almost all clinical situations, from surgically removed tumors to metastatic diseases. The 30% response rate usually reported in advanced disease (with a median survival of 10 months) has to be improved and a more global approach is nowadays mandatory, including targeted agents. This review sum-up the clinical situations in which gemcitabine can be prescribed (advanced disease), or shall be prescribed (adjuvant setting, combination with anti-angiogenic agent or EGFR inhibitors), and highlight opening questions.
吉西他滨研发过程中出现的问题反映了过去10年非小细胞肺癌（NSCLC）的发展历程。第三代治疗方法（吉西他滨、长春瑞滨和紫杉烷）与铂类化合物联合使用，如今几乎适用于所有临床情况，从手术切除的肿瘤到转移性疾病。晚期疾病通常报告的30%缓解率（中位生存期为10个月）必须提高，如今必须采取更全面的方法，包括靶向药物。本综述总结了吉西他滨可以应用（晚期疾病）或应该应用（辅助治疗、与抗血管生成药物或表皮生长因子受体抑制剂联合使用）的临床情况，并突出了尚未解决的问题。
